Ge Long Hui A P P·2025-12-24 09:46Core Viewpoint - Green Leaf Pharmaceutical (02186.HK) has signed a cooperation agreement with Jiangsu Enhua Pharmaceutical Co., Ltd. for exclusive commercialization rights of three long-acting injectable antipsychotic products in mainland China [1] Group 1: Agreement Details - The three products involved are Risperidone microspheres (Rykotuo), Paliperidone palmitate injection (Ruibailai), and Paliperidone palmitate injection (Meibiri), all indicated for the treatment of schizophrenia [1] - Enhua will be responsible for the exclusive distribution and commercialization of these products in mainland China, while Green Leaf retains ownership of the assets, registration certificates, and all intellectual property rights [1] - The agreement is set for a duration of ten years, with Enhua making a one-time non-refundable payment of $20 million as a licensing fee to Green Leaf [1] Group 2: Market Implications - This collaboration represents a strong partnership between two leading companies in the central nervous system (CNS) field, aiming to deepen the market presence for schizophrenia treatment [1] - The agreement is expected to provide patients with more comprehensive treatment options in the schizophrenia market [1]